Generic asenapine maleate gains US approval

The US regulator approved an abbreviated application from a generic manufacturer for asenapine maleate, the sublingual second-generation antipsychotic licensed for schizophrenia and bipolar I disorder. An abbreviated new drug application is a generic authorisation: it widens supply and tends to lower cost, rather than adding an indication or raising a safety concern.

For prescribers the practical effect is on access. More generic competition for asenapine can ease cost and availability, which matters most in settings where branded atypicals are unaffordable. The sublingual route stays the same, as do its quirks: it must dissolve under the tongue, with no eating or drinking for ten minutes, and oral hypoaesthesia is common.

Nothing about efficacy or safety changes with a generic approval. Prescribe and monitor asenapine exactly as before, and use the clinical sedation and metabolic profile, not novelty, to decide where it fits.

• A generic manufacturer received US approval for asenapine maleate, a sublingual second-generation antipsychotic.
• An abbreviated new drug application widens supply and tends to lower cost, not add an indication.
• Counsel on the sublingual technique: dissolve under the tongue, nothing to eat or drink for ten minutes.
• Efficacy, safety and monitoring are unchanged; prescribe as before.
• More generic competition may improve affordability where branded atypicals are costly.

Why it matters

Cost and availability decide which antipsychotic a patient can actually stay on, so a new generic matters for adherence even when nothing clinical changes.

Don't overread it

A generic (abbreviated) approval is administrative; it is not a new indication, a label expansion, or a safety finding.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.